Marker Therapeutics Inc (MRKR)

[poods]

As usual, spot on. We all know dilution is hanging over our heads, so it's a game of chicken with the CEO whether he has something else brewing with which he could stun the market (e.g. partnership, TPIV200 data, other solid tumor or hematologic malignancy responses, another PC CR pending, etc.) It's clear that this treatment works, both from the clinical responses in heavily pretreated patients and the correlative immune response data. A cancer treatment that works with no side effects! Hmmm If this was a charity, I give them money. For now, I'll just buy the stock. Easy decision at this level.